The same research group published a similar research that did not confirm the potential risk of angiotensin-converting enzyme (ACE) inhibitor or angiotensin II receptor blockers (ARBs) for in-hospital COVID-19 patients (Mehra et al., 2020b). This evidence concerns the gene ACE and COVID-19.